K
Karen McAdam
Researcher at Cambridge University Hospitals NHS Foundation Trust
Publications - 43
Citations - 1543
Karen McAdam is an academic researcher from Cambridge University Hospitals NHS Foundation Trust. The author has contributed to research in topics: Breast cancer & Epirubicin. The author has an hindex of 16, co-authored 37 publications receiving 1292 citations. Previous affiliations of Karen McAdam include University of Cambridge & Peterborough City Hospital.
Papers
More filters
Journal ArticleDOI
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton,Paul Silcocks,Trevor Cox,Juan W. Valle,Jonathan Wadsley,David Propper,Fareeda Y. Coxon,Paul Ross,Srinivasan Madhusudan,Tom Roques,David Cunningham,Stephen Falk,Nick Wadd,Mark Harrison,Pippa Corrie,Timothy Iveson,A. Robinson,Karen McAdam,Martin Eatock,Jeff Evans,Caroline Archer,Tamas Hickish,Angel Garcia-Alonso,Marianne Nicolson,W.P. Steward,Alan Anthoney,William Greenhalf,Victoria Shaw,Eithne Costello,Dean J. Naisbitt,Charlotte L. Rawcliffe,Gemma Nanson,John P. Neoptolemos +32 more
TL;DR: Adding GV1001 vaccination to chemotherapy did not improve overall survival and new strategies to enhance the immune response effect of telomerase vaccination were not found.
Journal ArticleDOI
Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer
Christopher J. Poole,Helena M. Earl,Louise Hiller,Janet A. Dunn,S. Bathers,Robert Grieve,David Spooner,R.K. Agrawal,I. N. Fernando,A Murray Brunt,S O'Reilly,S Michael Crawford,Daniel Rea,Peter Simmonds,Janine Mansi,Andrew Stanley,Peter Harvey,Karen McAdam,Liz Foster,Robert C. F. Leonard,Chris Twelves +20 more
TL;DR: Relapse-free and overall survival rates were significantly higher in the epirubicin-CMF groups than in the CMF-alone groups and the overall incidence of adverse effects was significantly higher with epirubsicin plus CMF than with CMF alone but did not significantly affect the delivered-dose intensity or the quality of life.
Journal ArticleDOI
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Helena M. Earl,Helena M. Earl,Helena M. Earl,Louise Hiller,Anne-Laure Vallier,Shrushma Loi,Karen McAdam,Karen McAdam,Luke Hughes-Davies,Adrian Harnett,Mei-Lin Ah-See,Richard Simcock,Daniel Rea,Sanjay Raj,Pamela Woodings,Mark Harries,Donna L. Howe,Kerry Raynes,Helen B Higgins,Maggie Wilcox,Chris Plummer,Chris Plummer,Janine Mansi,Ioannis Gounaris,Betania Mahler Araujo,Elena Provenzano,Elena Provenzano,Anita Chhabra,Jean Abraham,Jean Abraham,Jean Abraham,Carlos Caldas,Peter Hall,Christopher McCabe,Claire Hulme,Claire Hulme,David Miles,Andrew M Wardley,David Cameron,Janet A. Dunn,Roshan Agarwal,Hafiz Algurafi,Rozenn Allerton,Caroline Archer,Anne C Armstrong,Catherine Bale,Lisa H Barraclough,Urmila Barthakur,Carolyn Bedi,Kim Benstead,D. Bloomfield,Rebecca Bowen,Chris Bradley,Jane Brown,Mohammad Butt,Mark Churn,Susan Cleator,Joanne Cliff,Perric Crellin,Margaret Daly,Shiroma De Silva-Minor,A.S. Dhadda,O.S. Din,Sue Down,H. M. Earl,David J. Eaton,Andrew Eichholz,Daniel Epurescu,Chee Goh,Andrew D. Goodman,Robert Grieve,Maher Hadaki,Catherine Harper-Wynne,Larry Hayward,A. Humphreys,Helen Innes,Mariam Jafri,Apurna Jegannathen,Muireann Kelleher,Hartmut Kristeleit,Daniela Lee,Susan Lupton,Carol MacGregor,Zafar Malik,Jennifer Marshall,Trevor McGolick,Rakesh Mehra,Natasha Mithal,Charlotte Moss,Aian Moss,Mukesh Mukesh,Anthony Neal,Daniel Nelmes,Helen Neville-Webbe,Jacqueline Newby,S O'Reilly,Peter Ostler,Mojca Persic,Laura Pettit,Fharat A. Raja,Catherine Reed,Anne Rigg,Helen Roe,Nihal Shah,Peter Simmonds,Eliot Sims,Sarah Smith,Nicola Storey,Wendy Taylor,Narottam Thanvi,Karen Tipples,Jayant S. Vaidya,Mohini Varughese,Anup Vinayan,Nawaz Walji,Simon Waters,Kathryn Wright,Sundus Yahya +117 more
TL;DR: 6-month trastuzumab treatment is shown to be non-inferior to 12-month treatment in patients with HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse events, which support consideration of reduced duration trastzumab for women at similar risk of recurrence as to those included in the trial.
Journal ArticleDOI
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
X. Pivot,J. Gligorov,V. Müller,G. Curigliano,A. Knoop,S. Verma,V. Jenkins,Nana Scotto,S. Osborne,L. Fallowfield,Lesley Fallowfield,Valerie Jenkins,Justine Kilkerr,C. Langridge,Kathryn Monson,Erik Jakobsen,Mette Holck Nielsen,Soeren Linnet,Ann Knoop,Xavier Pivot,Hervé Bonnefoi,Mireille Mousseau,Laurent Zelek,Hugues Bourgeois,Claudia Plesse Lefeuvre,Thomas Bachelot,Thierry Petit,Etienne Brain,Christelle Levy,Joseph Gligorov,Doris Augustin,Heiko Graf,Georg Heinrich,Hendrik Kroening,Sherko Kuemmel,Volkmar Müller,Friedrich Overkamp,Tjoung-Won Park-Simon,Marcus Schmidt,Lidia Perlova-Griff,Christopher Wolf,Marco Colleoni,Alberto Ballestrero,Antonio Bernardo,Angela Stefania Ribecco,Luca Gianni,Giuseppe Curigliano,Elżbieta Brewczynska,Jacek Jassem,Vadim Shirinkin,Alexey Manikhas,Victoria Dvornichenko,Mikhail Lichinitser,Vladimir Semiglazov,Guzel Mukhametshina,Irina Bulavina,Enrique Espinosa Arranz,Francisco Carabantes Ocon,Guillermo López Vivanco,Javier Salvador Bofill,Ignacio Porras Quintela,Alfonso Sanchez Muñoz,Yolanda Fernández Pérez,Javier Cassinello Espinosa,José Valero Alvarez,Rodrigo Lastra del Prado,Luis De La Cruz Merino,José Manuel Pérez García,Santos Enrech Frances,Per Edlund,Bengt Norberg,Anna-Karin Wennstig,Pehr Lind,Nik Hauser,Christoph Tausch,Celalettin Camci,Fikret Arpaci,Huseyin Abali,Ruchan Uslu,Saad Tahir,Duncan Wheatley,Stephen L. Chan,Peter Barrett-Lee,Karen McAdam,Richard Simcock,Russell Burcombe,Robert El-Maraghi,Nadia Califaretti,Silvana Spadafora,Sandeep Sehdev,Amer Sami,Sunil Verma +91 more
TL;DR: Patient preference, healthcare professional satisfaction, and safety data pooled from PrefHer and HannaH confirm that s.c. trastuzumab is a validated and preferred option over i.v. for improving patients' care in HER2-positive breast cancer.
Journal ArticleDOI
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
Helena M. Earl,Helena M. Earl,Louise Hiller,Janet A. Dunn,Clare Blenkinsop,L Grybowicz,Anne-Laure Vallier,Jean Abraham,Jean Abraham,Jean Abraham,Jeremy Thomas,Elena Provenzano,Elena Provenzano,Luke Hughes-Davies,Ioannis Gounaris,Karen McAdam,Stephen Chan,Rizvana Ahmad,Tamas Hickish,Stephen Houston,Daniel Rea,John M. S. Bartlett,John M. S. Bartlett,Carlos Caldas,Carlos Caldas,David Cameron,Larry Hayward +26 more
TL;DR: Addition of four cycles of bevacizumab to D-FEC in HER2-negative early breast cancer significantly improved pathological complete response, however, whether the improvement in pathologicalcomplete response will lead to improved disease-free and overall survival outcomes is unknown.